Overview of Reviews

You have free access to this content

Pharmacological interventions for smoking cessation: an overview and network meta-analysis

  1. Kate Cahill*,
  2. Sarah Stevens,
  3. Rafael Perera,
  4. Tim Lancaster

Editorial Group: Cochrane Tobacco Addiction Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 16 NOV 2012

DOI: 10.1002/14651858.CD009329.pub2


How to Cite

Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD009329. DOI: 10.1002/14651858.CD009329.pub2.

Author Information

  1. University of Oxford, Department of Primary Care Health Sciences, Oxford, UK

*Kate Cahill, Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK. kate.cahill@phc.ox.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 31 MAY 2013

SEARCH

References

References to included reviews

  1. References to included reviews
  2. References to excluded reviews
  3. Additional references

References to excluded reviews

  1. References to included reviews
  2. References to excluded reviews
  3. Additional references

Additional references

  1. References to included reviews
  2. References to excluded reviews
  3. Additional references
Atkins 2004
  • Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al [GRADE Working Group]. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4.
Benowitz 2008
Beyens 2008
  • Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M. Serious Adverse Reactions of Bupropion for Smoking Cessation Analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Safety 2008;31:1017-26.
Boshier 2003
  • Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. European Journal of Clinical Pharmacology 2003;59(10):767-73.
Brooks 1998
  • Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998;7(4):434-45.
Bucher 1997
  • Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
Chun-Fai-Chan 2005
  • Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192(3):932-936.
Coleman 2012
CONSORT 1996
  • Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 1996;276(8):637-9.
Disease Control Priorities 2006
  • Disease Control Priorities Project. Tobacco Addiction. http://www.dcp2.org/file/52/DCPP-Tobacco.pdf (accessed 24th March 2013).
Dunner 1998
  • Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. Journal of Clinical Psychiatry 1998;59:366-73.
Ebbert 2011
Eisenberg 2008a
  • Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal 2008;179(2):135-44.
Eisenberg 2008b
Eisenberg 2013
  • Filion K, Eisenberg M. Personal communication 6th January 2013.
EMEA 2002
  • European Agency for the Evaluation of Medicines for Human Use. Committee for Proprietary Medicinal Products. Opinion following an article 36 referral. Bupropion hydrochloride. http://www.emea.eu.int/pdfs/human/referral/2761002en.pdf Accessed 29 April 2004.
Etter 2007
Evans 2009
  • Evans JR, Virgili G, Gordon I, Bunce C, Chakravarthy U, Desai P, et al. Interventions for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007650]
FDA 2011
  • U. S. Food, Drug Administration. FDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events. http://www.fda.gov/Drugs/DrugSafety/ucm276737.htm (accessed 19/1/2012) October 2011.
Fiore 1992
  • Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. JAMA 1992;268:2687-94.
Fiore 2008
  • Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. Rockville MD: US Department of Health and Human Services, 2008.
GlaxoSmithKline
  • GlaxoSmithKline. Zyban(R) bupropion hydrochloride Sustained-Release Tablets. Product Information. www.gsk.com/products/assets/us_zyban.pdf (accessed 15/11/2006).
GLS 2009
  • Office for National Statistics. Smoking and drinking among adults, 2009. A report on the 2009 General Lifestyle Survey. ONS, 2011.
Gonzales 2006
  • Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an α4ß2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296(1):47-55. [: clinicaltrials.gov ID: NCT00141206]
Greenland 1998
Gunnell 2009
  • Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805.
Hajek 2013
  • Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 2013 February 12 [Epub ahead of print]. [DOI: 10.1136/thoraxjnl-2012-203035]
Harrison-Woolrych 2011
  • Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Safety 2011;34(9):763-72.
Harrison-Woolrych 2012
  • Harrison-Woolrych M, Maggo S, Tan M, Savage R, Ashton J. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Safety 2012;35(1):33-43.
Hubbard 2005
  • Hubbard R, Lewis S, West J, Smith C, Godfrey C, Smeeth L, et al. Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network. Thorax 2005;60(10):848-50.
Hughes 2003
  • Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine & Tobacco Research 2003;5(1):13-25.
Jorenby 2006
  • Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an α4ß2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006;296(1):56-63. [: clinicaltrials.gov ID NCT00143364]
Joseph 1996
  • Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. New England Journal of Medicine 1996;335:1792-8.
Joseph 2003
Kasliwal 2009
  • Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Safety 2009;32(6):499-507.
Kotlyar 2005
Levine 2010
  • Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Bupropion and cognitive behavioural therapy for weight-concerned women smokers. Archives of Internal Medicine 2010;170(6):543-550.
Lu 2004
Lu 2006
Lumley 2009
Mallett 2002
  • Mallett S, Hopewell S, Clarke M. Grey literature in systematic reviews: The first 1000 Cochrane systematic reviews. Fourth symposium on systematic reviews: Pushing the boundaries. Oxford, 2002.
Meine 2005
  • Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. American Journal of Cardiology 2005;95:976-8.
Meyer 2013
MHRA 2004
  • Pharmacovigilance Information Unit, Medicines and Healthcare products Regulatory Agency (UK). Personal Communication 29 April 2004.
MHRA 2011
  • Medicines and Healthcare products Regulatory Agency. MHRA UK Public Assessment Report|: Nicobrevin: withdrawn from UK market as risks outweigh benefits. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con114612.pdf (accessed 20/11/2012) April 2011.
Mills 2012
  • Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Annals of Medicine 2012;44(6):588-97.
MMWR 2003
  • Centers for Disease Control and Prevention. Cigarette smoking-attributable morbidity - United States 2000. MMWR Sep 2003.
MMWR 2007
  • Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2006. MMWR 2007;56:1157-61.
Myung 2012
NHS 2008
  • The Information Centre for Health and Social Care. Statistics on smoking: England. National Health Service, 2008.
Palmer 1992
  • Palmer KJ, Buckley MM, Faulds D. Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992;44:498-529.
Planer 2011
  • Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Archives of Internal Medicine 2011;171(12):1055-60.
Plummer 2003
  • Plummer M. JAGS: a program for analysis of bayesian graphical models using gibbs sampling. Sourceforge ( https://sourceforge.net/projects/mcmc-jags), 2003.
Plummer 2012
  • Plummer M. RJAGS: Bayesian graphical models using MCMC (http://CRAN.R-project.org/package=rjags). Sourceforge (http://mcmc-jags.sourceforge.net), 2012.
Pollak 2007
  • Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, Pletsch PK, et al. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. American Journal of Preventive Medicine 2007;33:297-305.
Prochaska 2012
  • Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012;344:e2856.
RCP 2000
  • Royal College of Physicians. Tobacco Addiction in Britain: a report of the Tobacco Advisory Group of the Royal College of Physicians. http://old.rcplondon.ac.uk/pubs/books/nicotine/index.htm (accessed 19th April 2011) 2000.
Rigotti 2010
  • Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. Circulation 2010;121(2):221-9. [: clinicaltrials.gov ID: NCT00282984]
Scherer 2007
  • Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.MR000005.pub3]
SCOTH 1998
  • Department of Health. Report of the Scientific Committee on Tobacco and Health. http://www.archive.official-documents.co.uk/document/doh/tobacco/report.htm (accessed 19th April 2011) 1998.
Shea 2007
Shea 2011
  • Shea B. Personal communication August 2011.
Singh 2011
  • Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Canadian Medical Association Journal 2011;183(12):1359-66.
Spiegelhalter 2002
SRNT 2002
  • SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research 2002;4(2):149-59.
Stapleton 1998
  • Stapleton J. Cigarette smoking prevalence, cessation and relapse. Statistical Methods in Medical Research 1998;7(2):187-203.
Team 2012
  • Team RC. A language and environment for statistical computing. http://www.R-project.org (accessed 20/11/2012) 2012.
TGA 2004
  • Adverse Drugs Reactions Unit, Therapeutic Goods Administration (Australia). Personal Communication 31 March 2004.
Thorlund 2013
  • Thorlund K, Thabane L, Mills EJ. Modelling heterogeneity variances in multiple treatment comparison meta-analysis - Are informative priors the better solution?. Medical Research Methodology 2013 11 January [Epub ahead of print]; Vol. 13, issue 2. [DOI: 10.1186/1471-2288-13-2]
TNWG 1994
  • Transdermal Nicotine Working Group. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Archives of Internal Medicine 1994;154:989-95.
Tobacco Atlas 2010
  • Shafey O, Eriksen M, Ross H, Mackay J. The Tobacco Atlas. The Tobacco Atlas. 3rd Edition. World Health Organization, 2010.
Tonstad 2010
  • Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Safety 2010;33(4):289-301.
Tsoi 2010
Tønnesen 2012
UK Clinical Trials
  • Current Controlled Trials. metaRegister of Controlled Trials (mRCT). Springer Science+Business Media, http://www.controlled-trials.com/mrct/ (accessed 23rd May 2012).
US Clinical Trials
  • United States National Institutes of Health. ClinicalTrials.gov. USNIH, http://clinicaltrials.gov/ct2/home (accessed 23rd May 2012).
USFDA 2009a
  • Anon. Varenicline and bupropion. Reports of suicidality associated with used of varenicline (marketed as CHANTIX) and bupropion (marketed as Zyban and generics). FDA Drug Safety Newsletter 2009;2(1):1-4.
van der Meer 2009
  • van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006102]
van Valkenhoef 2012a
  • van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Research Synthesis Methods 2012. [DOI: 10.1002/jrsm.1054]
van Valkenhoef 2012b
  • van Valkenhoef G, Kuiper J. GeMTC: GeMTC network meta-analysis. http://CRAN.R-project.org/package=gemtc (accessed 20/11/2012) 2012.
Wallstrom 1999
West 2006
  • West R. Background smoking cessation rates in England. http://www.smokinginengland.info/Ref/paper2.pdf (accessed 19th April 2011) 2006.
WHO 2009
  • World Health Organization. 17th expert committee on the selection and use of essential medicines. http://www.who.int/selection_medicines/committees/expert/17/en/index.html (accessed 19th April 2011) 2009.
WHO trials registry platform
  • World Health Organization. Internation Clinical Trials Registry Platform Search Portal. WHO, http://apps.who.int/trialsearch/Default.aspx (accessed May 23rd 2012).
Williams 2007
  • Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research and Opinion 2007;23(4):793-801. [: clinical trials.gov ID: 00143299]
Wu 2006